The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Revisiting FDA Approval of Aducanumab
Open accessAbstract
Interview with Dr. Gil Rabinovici on the FDA’s controversial approval of a new treatment for Alzheimer’s disease. (16:39)Download Given the scientific, regulatory, and clinical implications of the accelerated FDA approval of aducanumab for Alzheimer’s disease, it’s essential to consider beta-amyloid’s suitability as a surrogate end point. Doing so casts doubt on the wisdom of the decision.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This decision was based on the effects of aducanumab on the surrogate endpoint of reduction of amyloid plaque in the brain of patients with AD, which at that point was not validated as being predictive of clinical benefit”
From The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics (2022) · cites this paper as [9]
In the citing paper
“The FDA has controversially granted accelerated approval to aducanumab and has opined that the reduction of amyloid is reasonably likely to predict clinical benefit 7,9,[98][99][100][101][102][103][104][105][106][107] .”
From The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics (2022) · cites this paper as [9]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Donanemab in Early Alzheimer’s Disease
Mintun, M. A., Lo, A. C., Duggan Evans, C., Wessels, A. M., Ardayfio, P. A., Andersen, S. W., Shcherbinin, S., Sparks, J., Sims, J. R., Brys, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2100708 · Cited by 1,728
Cited by
Sorted by citations
Lamptey, R. N. L., Chaulagain, B., Trivedi, R., Gothwal, A., Layek, B., & Singh, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031851 · Cited by 1,010
The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics
Karran, E., & De Strooper, B. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00391-w · Cited by 742
Connelly‐Smith, L. S., Alquist, C. R., Aqui, N. A., Hofmann, J. C., Klingel, R., Onwuemene, O. A., Patriquin, C. J., Pham, H. P., Sanchez, A. P., Schneiderman, J., et al. (2023) · Journal of Clinical Apheresis · doi:10.1002/jca.22043 · Cited by 751
The neuroimmune axis of Alzheimer’s disease
Jorfi, M., Maaser‐Hecker, A., & Tanzi, R. E. (2023) · Genome Medicine · doi:10.1186/s13073-023-01155-w · Cited by 313
The amyloid cascade hypothesis: an updated critical review
Kepp, K. P., Robakis, N. K. R. K., Høilund‐Carlsen, P. F., Sensi, S. L., & Vissel, B. (2023) · Brain · doi:10.1093/brain/awad159 · Cited by 315
Role of Aducanumab in the Treatment of Alzheimer’s Disease: Challenges and Opportunities
Vaz, M., Silva, V., Monteiro, C., & Silvestre, S. (2022) · Clinical Interventions in Aging · doi:10.2147/cia.s325026 · Cited by 183
“Secondly, there is no evidence that Aβ reduction correlates with clinical benefits, so the majority of experts consider that Aβ plaques are not a valid surrogate endpoint.(10,60) Moreover, recent studies showed that tau accumulation correlates better with cognitive impairment than Aβ.”
BackgroundLimorenko, G., & Lashuel, H. A. (2021) · Chemical Society Reviews · doi:10.1039/d1cs00127b · Cited by 168
Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease in the US
Ross, E. L., Weinberg, M. S., & Arnold, S. E. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2022.0315 · Cited by 151
Physiology and pharmacology of amyloid precursor protein
Cho, Y., Bae, H., Okun, E., Arumugam, T. V., & Jo, D. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108122 · Cited by 150
Michaeli, D. T., Michaeli, T., Albers, S., Boch, T., & Michaeli, J. C. (2023) · The European Journal of Health Economics · doi:10.1007/s10198-023-01639-x · Cited by 133
Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers
Golde, T. E. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01201-2 · Cited by 119
Peripheral immunity is associated with the risk of incident dementia
Zhang, Y.-R., Wang, J.-J., Chen, S.-F., Wang, H.-F., Li, Y.-Z., Ou, Y.-N., Huang, S.-Y., Chen, S.-D., Cheng, W., Feng, J.-F., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01446-5 · Cited by 114
Physiological β-amyloid clearance by the liver and its therapeutic potential for Alzheimer’s disease
Cheng, Y., He, C.-Y., Tian, D.-Y., Chen, S.-H., Ren, J.-R., Sun, H.-L., Xu, M.-Y., Tan, C.-R., Fan, D.-Y., Jian, J.-M., et al. (2023) · Acta Neuropathologica · doi:10.1007/s00401-023-02559-z · Cited by 110
Anti-Amyloid Therapies for Alzheimer’s Disease and the Amyloid Cascade Hypothesis
Fedele, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914499 · Cited by 102
Ebell, M. H., Barry, H. C., Baduni, K., & Grasso, G. (2024) · The Annals of Family Medicine · doi:10.1370/afm.3050 · Cited by 100
Lacorte, E., Ancidoni, A., Zaccaria, V., Remoli, G., Tariciotti, L., Bellomo, G., Sciancalepore, F., Corbo, M., Lombardo, F. L., Bacigalupo, I., et al. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220046 · Cited by 104
Synaptogenic effect of APP -Swedish mutation in familial Alzheimer’s disease
Zhou, B., Lu, J. G., Siddu, A., Wernig, M., & Südhof, T. C. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn9380 · Cited by 99
Alzheimer’s disease – the journey of a healthy brain into organ failure
Golde, T. E. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00523-1 · Cited by 98
Villain, N., Planche, V., & Levy, R. (2022) · Revue Neurologique · doi:10.1016/j.neurol.2022.06.012 · Cited by 87
Prodromal Parkinson's disease: hype or hope for disease-modification trials?
Mahlknecht, P., Marini, K., Werkmann, M., Poewe, W. H., & Seppi, K. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00286-1 · Cited by 71
How the immune system shapes neurodegenerative diseases
Mason, H. D., & McGavern, D. B. (2022) · Trends in Neurosciences · doi:10.1016/j.tins.2022.08.001 · Cited by 67
Natural Polyphenolic Nanodots for Alzheimer's Disease Treatment
Yang, P., Huang, Q., Zhang, J., Li, Y., Gao, H., & Gu, Z. (2023) · Advanced Materials · doi:10.1002/adma.202308393 · Cited by 67
Lessons Learned from Approval of Aducanumab for Alzheimer's Disease
Heidebrink, J. L., & Paulson, H. L. (2024) · Annual Review of Medicine · doi:10.1146/annurev-med-051022-043645 · Cited by 61
Vokinger, K. N., Kesselheim, A. S., Glaus, C., & Hwang, T. J. (2022) · JAMA Health Forum · doi:10.1001/jamahealthforum.2022.2685 · Cited by 56
Self-citationThe Anti-Amyloid Monoclonal Antibody Lecanemab: 16 Cautionary Notes
Kepp, K. P., Sensi, S. L., Johnsen, K. B., Barrio, J. R., Høilund‐Carlsen, P. F., Neve, R. L., Alavi, A. A., Herrup, K., Perry, G. L., Robakis, N. K. R. K., et al. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230099 · Cited by 56
Beyond Amyloid and Tau: The Critical Role of Microglia in Alzheimer’s Disease Therapeutics
Dias, D., & Socodato, R. (2025) · Biomedicines · doi:10.3390/biomedicines13020279 · Cited by 60
Transplantation of Nasal Olfactory Mucosa Mesenchymal Stem Cells Benefits Alzheimer’s Disease
Hong, C., Chen, M., Duan, R., Wang, X., Pang, Z., Ge, L., Lü, M., Xie, H., & Liu, Z. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-03044-6 · Cited by 44
Long Non-coding RNA: Insight Into Mechanisms of Alzheimer's Disease
Lan, Z., Chen, Y., Jin, J., Xu, Y., & Zhu, X. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.821002 · Cited by 45
An Appropriate Use of Accelerated Approval — Aducanumab for Alzheimer’s Disease
Dunn, B., Stein, P., Temple, R., & Cavazzoni, P. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2111960 · Cited by 42
Sarazin, M., Lagarde, J., Haddad, I., de Souza, L. C., Bellier, B., Potier, M., Bottlaender, M., & Dorothée, G. (2024) · Nature Aging · doi:10.1038/s43587-024-00630-2 · Cited by 42
Pascual‐Lucas, M., Allué, J. A., Sarasa, L., Fandos, N., Castillo, S., Terencio, J. V., Sarasa, M., Tartari, J. P., Sanabria, Á., Tárraga, L., et al. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01143-z · Cited by 41
Uchida, K. (2022) · Cells · doi:10.3390/cells11050919 · Cited by 41
Tondo, G., Marchi, F. D., Bonardi, F., Menegon, F., Verrini, G., Aprile, D., Anselmi, M., Mazzini, L., & Comi, C. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13113098 · Cited by 45
Ushering in a New Era of Alzheimer Disease Therapy
Widera, E., Brangman, S. A., & Chin, N. A. (2023) · JAMA · doi:10.1001/jama.2023.11701 · Cited by 36
Lessons from antiamyloid-β immunotherapies in Alzheimer's disease
Plascencia‐Villa, G., & Perry, G. L. (2023) · Handbook of clinical neurology · doi:10.1016/b978-0-323-85555-6.00019-9 · Cited by 35
Sovateltide Mediated Endothelin B Receptors Agonism and Curbing Neurological Disorders
Ranjan, A. K., & Gulati, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063146 · Cited by 35
Mantik, K. E. K., Kim, S., Gu, B., Moon, S., Kwak, H., Park, D., & Kang, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411450 · Cited by 36
Boosting mitochondrial health to counteract neurodegeneration
Burtscher, J., Romani, M., Bernardo, G., Popa, T., Ziviani, E., Hummel, F. C., Sorrentino, V., & Millet, G. P. (2022) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2022.102289 · Cited by 36
Recent Insights into the Neurobiology of Alzheimer’s Disease and Advanced Treatment Strategies
Anitha, K., Singh, M. K., Kohat, K., Varshini, T. S., Chenchula, S., Padmavathi, R., Amerneni, L. S., Vishnu Vardhan, K., Mythili Bai, K., Chavan, M. R., et al. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04384-1 · Cited by 35
“Real‐world” eligibility for aducanumab depends on clinical setting and patients' journey
Padovani, A., Caratozzolo, S., Rozzini, L., Pilotto, A., Benussi, A., & Tedeschi, G. (2021) · Journal of the American Geriatrics Society · doi:10.1111/jgs.17530 · Cited by 31
Yeo-Teh, N. S. L., & Tang, B. L. (2023) · Science and Engineering Ethics · doi:10.1007/s11948-022-00422-0 · Cited by 28
Oosthoek, M., Vermunt, L., de Wilde, A., Bongers, B., Antwi‐Berko, D., Scheltens, P., van Bokhoven, P., Vijverberg, E. G. B., & Teunissen, C. E. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01456-1 · Cited by 36
Behavioral Interventions in Mild Cognitive Impairment (MCI): Lessons from a Multicomponent Program
Levy, S.-A. T., Smith, G. E., Wit, L. D., DeFeis, B. L., Ying, G., Amofa, P., Locke, D. E. C., Shandera‐Ochsner, A. L., McAlister, C. B., Phatak, V. S., et al. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01225-8 · Cited by 30
Physicians’ Perspectives On FDA Regulation Of Drugs And Medical Devices: A National Survey
Dhruva, S. S., Kesselheim, A. S., Woloshin, S., Ji, R. Z., Lu, Z., Darrow, J. J., & Redberg, R. F. (2024) · Health Affairs · doi:10.1377/hlthaff.2023.00466 · Cited by 25
Self-citationCalcium signaling hypothesis: A non-negligible pathogenesis in Alzheimer’s disease
Wang, M., Zhang, H., Liang, J., Huang, J., Wu, T., & Chen, N. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.01.007 · Cited by 29
Extending the US Food and Drug Administration’s Postmarket Authorities
Lynch, H. F., Sachs, R. E., Lee, S., Herder, M., Ross, J. S., & Ramachandran, R. (2023) · JAMA Health Forum · doi:10.1001/jamahealthforum.2023.1313 · Cited by 25
Converged avenues: depression and Alzheimer’s disease– shared pathophysiology and novel therapeutics
Bajaj, S., & Mahesh, R. (2024) · Molecular Biology Reports · doi:10.1007/s11033-023-09170-1 · Cited by 25
Lynch, H. F., Caplan, A. L., Furlong, P., & Bateman-House, A. (2021) · The American Journal of Bioethics · doi:10.1080/15265161.2021.1974975 · Cited by 23
What have we learned from past failures of investigational drugs for Alzheimer’s disease?
Imbimbo, B. P., & Watling, M. I. L. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.2017881 · Cited by 24
Donanemab: Conflicts of interest found in FDA committee that approved new Alzheimer’s drug
Lenzer, J., & Brownlee, S. (2024) · BMJ · doi:10.1136/bmj.q2010 · Cited by 24
p53: from understanding its structure to advances in therapeutic targeting
Wang, W., Liu, X., Liu, H., Abolhassani, H., Yan, H., Zhang, H., & Wang, X. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02549-5 · Cited by 29
Combination Therapy in Alzheimer’s Disease: Is It Time?
Salehipour, A., Bagheri, M., Sabahi, M., Dolatshahi, M., & Boche, D. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215680 · Cited by 22
Lian, Y., Jia, Y., Wong, J., Zhou, X., Song, W., Guo, J., Masters, C. L., & Wang, Y. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02324-4 · Cited by 25
Cheng, Y., ZAMRINI, E. Y., Faselis, C. J., Redd, D., Shao, Y., Morgan, C. J., Sheriff, H. M., Ahmed, A., Kokkinos, P. F., & Zeng‐Treitler, Q. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.12998 · Cited by 20
Chiong, W., Tolchin, B. D., Bonnie, R. J., Busl, K. M., Cruz‐Flores, S., Epstein, L. G., Greene, E. P., Illes, J., Kirschen, M. P., Larriviere, D. G., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000013053 · Cited by 19
Luo, J. J., Wallace, W., & Kusiak, J. W. (2022) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2022.120294 · Cited by 17
Johnston, J. L., Ross, J. S., & Ramachandran, R. (2023) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2022.6444 · Cited by 18
The Neuroimmunology of Multiple Sclerosis: Fictions and Facts
Pachner, A. R. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2021.796378 · Cited by 19
Li, J., Wu, X., Tan, X., Wang, S., Qu, R., Wu, X., Chen, Z., Wang, Z., & Chen, G. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1257973 · Cited by 20
DiStefano, M. J., Alexander, G. C., Polsky, D. E., & Anderson, G. F. (2022) · Journal of the American Geriatrics Society · doi:10.1111/jgs.17692 · Cited by 15
Self-citationRegulatory miRNAs in Cardiovascular and Alzheimer’s Disease: A Focus on Copper
Sacco, A., Martelli, F., Pal, A., Saraceno, C., Benussi, L., Ghidoni, R., Rongioletti, M. C. A., & Squitti, R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063327 · Cited by 16
Observational studies in Alzheimer disease: bridging preclinical studies and clinical trials
Brenowitz, W. D., & Yaffe, K. S. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00733-7 · Cited by 16
Das, V., Miller, J. H., Goud, A. C., Annadurai, N., Sanctis, J. B. D., Hrubá, L., & Hajdúch, M. (2024) · Medicinal Research Reviews · doi:10.1002/med.22033 · Cited by 16
Gui, G., & Hourigan, C. S. (2022) · The Cancer Journal · doi:10.1097/ppo.0000000000000572 · Cited by 15
Danziger, R., Fuchs, D.-T., Koronyo, Y., Rentsendorj, A., Sheyn, J., Hayden, E. Y., Teplow, D. B., Black, K. L., Fuchs, S., Bernstein, K. E., et al. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1179315 · Cited by 16
Intruders or protectors – the multifaceted role of B cells in CNS disorders
Aspden, J. W., Murphy, M. A., Kashlan, R. D., Xiong, Y., Poznansky, M. C., & Sîrbulescu, R. F. (2024) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2023.1329823 · Cited by 16
Fighting fire with fire: The immune system might be key in our fight against Alzheimer’s disease
Dujardin, P., Vandenbroucke, R. E., & Hoecke, L. V. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.01.004 · Cited by 14
Eugenitol ameliorates memory impairments in 5XFAD mice by reducing Aβ plaques and neuroinflammation
Cho, E., Youn, K., Kwon, H., Jeon, J., Cho, W., Park, S. J., Son, S. H., Jang, D. S., Shin, C. Y., Moon, M., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112763 · Cited by 13
Manna, P. R., Kshirsagar, S., Pradeepkiran, J. A., Rawat, P., Kumar, S., Reddy, A. P., & Reddy, P. H. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166738 · Cited by 14
Cullen, N. C., Janelidze, S., Stomrud, E., Bateman, R. J., Palmqvist, S., Hansson, O., & Mattsson, N. (2023) · Brain Communications · doi:10.1093/braincomms/fcad015 · Cited by 14
Dhruva, S. S., Kesselheim, A. S., Woloshin, S., Ji, R. Z., Lu, Z., Darrow, J. J., & Redberg, R. F. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2954 · Cited by 13
Self-citationPokrzyk, J., Kulczyńska‐Przybik, A., Guzik-Makaruk, E. M., Winkel, I., & Mroczko, B. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051935 · Cited by 14
Dynamic protein structures in normal function and pathologic misfolding in systemic amyloidosis
Lewkowicz, E., & Gursky, O. (2021) · Biophysical Chemistry · doi:10.1016/j.bpc.2021.106699 · Cited by 13
Amylin and Secretases in the Pathology and Treatment of Alzheimer’s Disease
Singh, S. P., Yang, F., Sivils, A., Cegielski, V., & Chu, X. (2022) · Biomolecules · doi:10.3390/biom12070996 · Cited by 11
Moving the U.S. Food and Drug Administration Forward
Perlmutter, J. S. (2021) · Annals of Internal Medicine · doi:10.7326/m21-3393 · Cited by 11
Self-citationActive Immunotherapy for the Prevention of Alzheimer’s and Parkinson’s Disease
Vroom, M. M., & Dodart, J. (2024) · Vaccines · doi:10.3390/vaccines12090973 · Cited by 10
Clark, S. L., Hartwell, E. E., Choi, D., Krystal, J. H., Messing, R. O., & Ferguson, L. B. (2024) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.15476 · Cited by 11
Sorum, P. C., Stein, C. M., & Moore, D. L. (2023) · The Journal of Law Medicine & Ethics · doi:10.1017/jme.2023.52 · Cited by 9
Protein kinases as therapeutic targets for Alzheimer’s disease: a brief review
Silva, I. M. F., Franco, G. D. R. R., Gontijo, V. S., & Viegas, C. (2024) · Exploration of Neuroprotective Therapy · doi:10.37349/ent.2024.00092 · Cited by 9
Vianello, C., Salluzzo, M., Anni, D., Boriero, D., Buffelli, M., & Carboni, L. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20054540 · Cited by 10
Kim, J. E., Tamres, L. K., Orbell, S. L., Cheng, R., Klunk, W. E., Aizenstein, H. J., Butters, M. A., McDade, E., & Lingler, J. H. (2023) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2023.08.005 · Cited by 10
Improving the Use of FDA Advisory Committees
Daval, C. J. R., Kesselheim, A. S., & Sarpatwari, A. (2022) · New England Journal of Medicine · doi:10.1056/nejmp2206492 · Cited by 9
Self-citationYu, Y., Zhang, N., Xiang, B., Ding, N., Liu, J., Huang, J., Zhao, M., Zhao, Y., Wang, Y., & Ma, Z. (2023) · Neurophotonics · doi:10.1117/1.nph.10.1.015005 · Cited by 9
Shahzad, M., Naci, H., Esselen, K. M., Dottino, J. A., & Wagner, A. K. (2024) · Journal of Pharmaceutical Policy and Practice · doi:10.1080/20523211.2024.2351003 · Cited by 8
Abushakra, S. R., Doraiswamy, P. M., Hey, J. A., Tosun, D., Barkhof, F., Barakos, J. A., Petrella, J. R., Kesslak, J. P., Power, A., Sabbagh, M. N., et al. (2025) · CNS Drugs · doi:10.1007/s40263-025-01251-y · Cited by 11
Pan, C., Chu, C., Chen, C., Chuang, Y., & Chen, N.-C. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18168576 · Cited by 8
Santos, R. X., Melis, V., Goatman, E. A., Leith, M., Baddeley, T. C., Storey, J. M. D., Riedel, G., Wischik, C. M., & Harrington, C. R. (2022) · Biomedicines · doi:10.3390/biomedicines10040867 · Cited by 8
Optimizing the Aging Brain: The BEAD Study on the Ethics of Dementia Prevention
Andreoletti, M., Lazzaroni, C., Petersen, N., Segawa, S., Leibing, A., Schicktanz, S., & Blasimme, A. (2023) · The Journal of Frailty & Aging · doi:10.14283/jfa.2023.6 · Cited by 7
Manna, P. R., Yang, S., Manna, C., Waters, H., Islam, M. A., Reddy, A. P., Rawat, P., & Reddy, P. H. (2024) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2024.105969 · Cited by 7
FDA-Approved Passive Immunization Treatments Against Aβ in Alzheimer’s Disease: Where Are We Now?
Higgins, M. J., Wasef, V., & Kwakowsky, A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27020883 · Cited by 7
Predicting amyloid‐beta pathology in the general population
Ho, P. T. N., van Arendonk, J., Steketee, R. M. E., van Rooij, F. J. A., Roshchupkin, G. V., Ikram, M. A., Vernooij, M. W., & Neitzel, J. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13161 · Cited by 7
Chin, N. A., Widera, E., Brangman, S. A., & Karlawish, J. H. (2023) · Journal of the American Geriatrics Society · doi:10.1111/jgs.18652 · Cited by 8
Neumann, P. J., Crummer, E., Chambers, J. D., & Tunis, S. (2023) · Milbank Quarterly · doi:10.1111/1468-0009.12670 · Cited by 5
Schwab, K., Robinson, L., Annschuetz, A., Dreesen, E., Magbagbeolu, M., Melis, V., Theuring, F., Harrington, C. R., Wischik, C. M., & Riedel, G. (2024) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2024.111172 · Cited by 4
Vokinger, K. N., Serra‐Burriel, M., Glaus, C., Welti, L., Ross, J. S., & Kesselheim, A. S. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-03242 · Cited by 5
Self-citationThe Real Question the FDA Is Asking Its Advisory Committees
Kanter, G. P. (2023) · JAMA Health Forum · doi:10.1001/jamahealthforum.2023.1234 · Cited by 5
PET in neurotherapeutic discovery and development
Chassé, M., & Vasdev, N. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00498 · Cited by 5
Tan, Y. L., Zhang, J., Yang, K., Xu, Z., Zhang, H., Chen, W., Peng, T., Wang, X., Liu, Z., Wei, P., et al. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210652 · Cited by 5
Chemical‐Driven Outflow of Dissociated Amyloid Burden from Brain to Blood
Lee, D.-H., Kim, H. V., Kim, H. Y., & Kim, Y. (2022) · Advanced Science · doi:10.1002/advs.202104542 · Cited by 4
Fukuda, H., Maeda, M., Murata, F., & Murata, Y. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220200 · Cited by 5
Metadata
- Authors
- Alexander, G. C., Knopman, D. S., Emerson, S. S., Ovbiagele, B., Kryscio, R. J., Perlmutter, J. S., & Kesselheim, A. S.
- Affiliations
- Brigham and Women's Hospital (US)
- Mayo Clinic (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-08-26
- Volume
- 385
- Issue
- 9
- Pages
- 769-771
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC11694499
- OpenAlex
- W3185118626
- Cited by
- 162
- References
- 1
- Citations by year
- 2026: 10 · 2025: 19 · 2024: 33 · 2023: 36 · 2022: 48 · 2021: 16
- FWCI
- 20.86
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Neurological Disorders and Stroke (RF1NS075321, R01NS103957, R01NS107281, R01NS075321)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Nursing › Issues, ethics and legal aspects › Biomedical Ethics and Regulation
- Keywords
- aducanumab, FDA drug approval, Alzheimer's disease, amyloid-beta, surrogate endpoints, accelerated approval, anti-amyloid therapy, regulatory decision-making
- MeSH terms
- Alzheimer Disease, Humans, Time Factors, United States, United States Food and Drug Administration, Biomarkers, Amyloid beta-Peptides, Drug Approval, Advisory Committees, Plaque, Amyloid, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
